 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. Nasdaq:HGEN Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumabTM, today announced that it has priced its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of 18.50 per share, resulting in gross proceeds to Humanigen of approximately 92.5 million, before deducting un 